For decades, the pharmacological management of CVDs has relied on cornerstone therapies, including angiotensin-converting enzyme (ACE) inhibitors for hypertension and heart failure (HF) [3], beta-blockers for angina, arrhythmias, and post-myocardial infarction care [4], and statins, which revolutionized atherosclerosis prevention by significantly lowering LDL cholesterol and reducing cardiovascular events [5]. Here, ACE is linked to angina pectoris.